Concordia Healthcare buys international niche medicines firm

September 8, 2015 12:36 PM

50 0

Canadian healthcare group Concordia (NASDAQ:CXRX, TSE:CXR) is to pay US$3.5bn to acquire Amdipharm Mercury in a cash plus stock deal.

European private equity group Cinven has agreed to sell Amdipharm for £800mln (circa US$1.2bn) plus 8.49mln common shares of Concordia, valued at around US$0.7bn, while Concordia will also take on around US$1.4bn of the acquired company’s debt.

Also read: AT&T’s $85.4B deal for Time Warner: A new bet on synergy

Read more

To category page